ESTRELLA IMMUNOPHARMA, INC. Accrued Marketing Costs, Current
ESTRELLA IMMUNOPHARMA, INC. (ESLA) had Accrued Marketing Costs, Current of $120.98 thousand as of 2023-09-30, per its 10-Q filed 2023-11-20.
Discontinued › Notes › Payables and Accruals
us-gaap:AccruedMarketingCostsCurrent · last filed 2023-11-20
- 2023-09-30: Accrued Marketing Costs, Current $120.98K.
- 2023-06-30: Accrued Marketing Costs, Current $116.48K.
| Period end | Accrued Marketing Costs, Current |
|---|---|
| 2023-09-30 | $120.98K 10-Q · filed 2023-11-20 |
| 2023-06-30 | $116.48K 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |